#USA #Los Angeles #Securities Fraud #Capricor Therapeutics #SBS Law

Investors Unite: A Call to Action

In a significant legal development, Schall, Brown & Schwartz LLP (SBS), a leading national firm specialized in shareholder rights, is calling upon investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) to take part in a class action lawsuit against the company. This comes in response to allegations of securities fraud related to the firm’s handling of a Biologics License Application (BLA) for its product, Deramiocel.

Understanding the Allegations

The lawsuit asserts that Capricor made misleading statements regarding its clinical data and the subsequent analysis used to support its regulatory application to the FDA. According to the complaint, these misrepresentations occurred despite the fact that changes to the statistical analysis plan were not approved by the FDA prior to the resubmission of the BLA. This breach raises significant concerns about the sufficiency of evidence presumably backing the product's effectiveness, ultimately leading to a material misrepresentation to investors.

The expectation is clear: shareholders who purchased stocks during the defined class period—ranging from December 17, 2025, to July 26, 2026—are particularly urged to seek participation in the case. Even if they were not lead plaintiffs, their involvement could provide a pathway for financial recovery if the allegations are validated. The deadline to join the lawsuit is fast approaching, closing on September 28, 2026.

Legal Support for Investors

SBS highlights that potential lead plaintiffs are not obliged to recover losses through direct participation, yet doing so could greatly enhance their chances of restitution. This class action represents an opportunity for affected investors to unite and challenge the alleged wrongdoing of the company, sending a clear signal that accountability in the corporate sphere remains paramount.

Prior to making any decisions, affected individuals are encouraged to contact SBS for a free discussion about their rights. Legal experts, including Brian Schall or David Schwartz, stand ready to provide assistance and facilitate the potential course of action tailored to the unique circumstances of each investor.

Your Rights Matter

As it stands, the case has yet to receive certification, which means investors who refrain from taking any action may not be legally represented in the proceedings. For those who believe they may have suffered losses due to the alleged fraudulent activities of Capricor, this is a critical juncture.

Taking action now may prove to be crucial for attaining justice. Coinciding with the gravity of these accusations, it presents an opportunity for shareholders to reclaim their confidence in the markets by enforcing their rights as investors. If you have faced losses due to what is alleged to be securities fraud, it is essential to consult with a legal professional at SBS.

Join the Movement

The ramifications of corporate missteps reach far beyond financial loss; they challenge the trust investors place in the healthcare sector. By taking a stand through involvement in this class action lawsuit, you are not just advocating for your own interests but also for the integrity of all shareholders within this industry.

Join the ranks of your fellow investors in the pursuit of justice against Capricor Therapeutics, Inc. for the alleged failures and deceptive practices. To learn more about the terms of participation, reach out to SBS today or visit their official website.

Act now—protect your interests and invest in justice.